Introduction {#s1}
============

Mitochondria (mt) are organelles that are susceptible to oxidative stress. The presence of excessive amounts of reactive oxidative species (ROS) results in mitochondrial oxidative damage and inefficient repair of mtDNA [@pone.0041125-doRosarioMarinho1]--[@pone.0041125-Rose1]. This can contribute to pathophysiological processes, including aging, degenerative disease [@pone.0041125-Mao1]--[@pone.0041125-Karbowski1] and cancer [@pone.0041125-Sotgia1]. In these circumstances, somatic mutations are also generated [@pone.0041125-He1].

The displacement loop (D-loop) regions of mtDNA does not encode any functional proteins [@pone.0041125-Chen1], [@pone.0041125-Penta1] and is known to accumulate mutations at a higher frequency than other regions of mtDNA in the setting of increased oxidative stress [@pone.0041125-Clayton1]. The D-loop contains the initial site of heavy chain replication and the promoters for heavy and light chain transcription. Therefore, it is responsible for the regulation of mtDNA replication and transcription [@pone.0041125-Penta1], [@pone.0041125-Clayton1]. The D-loop is highly polymorphic, and some polymorphisms are associated with aging [@pone.0041125-Michikawa1]--[@pone.0041125-Zhang1], coronary artery disease [@pone.0041125-Mueller1], and a variety of tumors, including lung [@pone.0041125-Suzuki1], colorectal [@pone.0041125-Lievre1], liver [@pone.0041125-Wang2], gastric [@pone.0041125-Wu1], breast [@pone.0041125-Parrella1], cervical [@pone.0041125-GoiaRusanu1], melanoma [@pone.0041125-Ebner1], head and neck [@pone.0041125-Ha1], oral [@pone.0041125-Liu1], and kidney [@pone.0041125-Nagy1] cancers. However, D-loop polymorphisms are not associated with prostate cancer [@pone.0041125-Mueller2],[@pone.0041125-Kim1]. Most of these D-loop studies focus on some cancer-associated single nucleotide polymorphisms (SNPs) for mtDNA, which were accompanied by poly-C tract alterations [@pone.0041125-Parrella1], [@pone.0041125-Ha1], [@pone.0041125-Liu1], [@pone.0041125-Nomoto1], [@pone.0041125-Wada1]. However, D-loop polymorphisms have not been systematically characterized in chronic dialysis patients.

Complications of chronic kidney disease (CKD) promote morbidity and mortality [@pone.0041125-Lenz1]. CKD patients can be classified according to kidney function along a continuum from mild renal dysfunction to irreversible kidney failure. CKD increases oxidative stress [@pone.0041125-Himmelfarb1] which has been demonstrated to influence mtDNA content in CKD patients [@pone.0041125-Chen2], [@pone.0041125-Wang3].

Because the D-loop region susceptible to oxidative stress, we hypothesized that specific SNP patterns in the D-loop of chronic dialysis patients may serve as potential genetic markers for chronic dialysis. To examine this hypothesis, we performed D-loop sequencing and used bioinformatic tools to identify SNPs that were associated with chronic dialysis when compared to healthy controls.

10.1371/journal.pone.0041125.t001

###### Basic demographic characteristics of patients and controls.
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                              patients   controls   Chi-square           
  -------- ----------- ----- ---------- ---------- ------------ -------- ----------
  Total                 897     193        21.5        704        78.5   
  Sex        female     427     115        59.6        312        44.3     0.0002
              male      470      78        40.4        392        55.7   
  Age          ≤50      422      97        50.3        325        46.2     0.3127
              \>50      475      96        49.7        379        53.8   
            Mean (SD)           49.0      (13.9)       51.9      (12.9)    0.0055
  DM            N       836     161        83.4        675        98.3    \<0.0001
                Y       44       32        16.6         12        1.7    
  CHD           N       854     170        88.1        684        98.4    \<0.0001
                Y       34       23        11.9         11        1.6    
  HT            N       593     109        56.5        484        69.6     0.0006
                Y       295      84        43.5        211        30.4   
  Smoke         N       698     170        88.1        528        75.0     0.0001
                Y       199      23        11.9        176        25.0   
  BMI       Mean (SD)           22.3      (3.8)        24.5      (3.5)    \<0.0001
  TBARS     Mean (SD)           1.1       (0.6)        1.2       (0.8)     0.0801
  Thiols    Mean (SD)           1.5       (0.5)        2.0       (0.4)    \<0.0001
  TG        Mean (SD)          169.5     (128.1)      130.4      (85.7)   \<0.0001
  Chol      Mean (SD)          189.4      (35.7)      202.1      (37.9)   \<0.0001

Abbreviations and/or units: CHD: coronary heart disease, HT: hypertension, BMI: body mass index, TBARS: thiobarbituric acid reactive substance (µM), Thiols (µM); TG: triglyceride (mg/dL), Chol: cholesterol (mg/dL).

Materials and Methods {#s2}
=====================

Subjects {#s2a}
--------

We enrolled 704 unrelated Taiwanese of ethnic Chinese background in this study through the hospital health examination center after giving consent. Participants included 312 men and 392 women with a mean age of 51.9 years. We enrolled 193 dialysis patients from the outpatient dialysis unit of the same hospital. They were composed of 78 men and 115 women with a mean age of 49 years. Venous blood samples were collected after overnight fasting. The serum was separated using a centrifuge and stored at −80°C. DNA was isolated from leucocytes using PUREGENE® DNA Purification kit (Gentra, Minneapolis, MN, USA) and stored at −20°C. The protocol for the present study was approved by the Committee on Human Research at Kaohsiung Chang Gung Memorial Hospital (CMRPG850271, CMRPG850272, CMRPG850242, CMRPG850252, IRB 95-0395B) and conducted in accordance with the Declaration of Helsinki. All participants signed a written informed consent form to obtain the approval for participation in this study.

Assessment of Oxidative and Anti-oxidative Stress Capacities {#s2b}
------------------------------------------------------------

Serum free thiols were determined by direct reaction of the thiols with 5,5-dithiobis(2-nitrobenzoic acid) (DTNB) to form 5-thio-2-nitrobenzoic acid (TNB). The amount of thiols was calculated from the absorbance determined using the extinction coefficient of TNB (A412 = 13,600 M^−1^ cm^−1^). The serum thiobarbituric acid reactive substance (TBARS) concentration was assessed according to the method of Ohkawa *et al.* [@pone.0041125-Ohkawa1]. Results are expressed as micromoles of TBARS per liter. A standard curve of TBARS was obtained by hydrolysis of 1,1,3,3-tetraethoxypropane (TEPP).

10.1371/journal.pone.0041125.t002

###### SNP identification from aligned sequences of cases and controls and their positional information.
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  SNP No.    Align-position[\*](#nt102){ref-type="table-fn"}1   D-loop position[\*](#nt102){ref-type="table-fn"}2   IUPAC code   SNP No.   Align-position[\*](#nt102){ref-type="table-fn"}1   D-loop position[\*](#nt102){ref-type="table-fn"}2   IUPAC code
  --------- -------------------------------------------------- --------------------------------------------------- ------------ --------- -------------------------------------------------- --------------------------------------------------- ------------
  **1**                             51                                                16051                             R        **40**                          298                                                16298                             Y
  **2**                             86                                                16086                             Y        **41**                          304                                                16304                             Y
  **3**                             92                                                16092                             H        **42**                          309                                                16309                             R
  **4**                             93                                                16093                             Y        **43**                          311                                                16311                             Y
  **5**                            108                                                16108                             Y        **44**                          316                                                16316                             R
  **6**                            111                                                16111                             Y        **45**                          319                                                16319                             R
  **7**                            126                                                16126                             Y        **46**                          324                                                16324                             Y
  **8**                            129                                                16129                             R        **47**                          327                                                16327                             Y
  **9**                            136                                                16136                             Y        **48**                          335                                                16335                             R
  **10**                           140                                                16140                             Y        **49**                          355                                                16355                             Y
  **11**                           145                                                16145                             R        **50**                          356                                                16356                             Y
  **12**                           148                                                16148                             Y        **51**                          357                                                16357                             Y
  **13**                           157                                                16157                             Y        **52**                          362                                                16362                             Y
  **14**                           162                                                16162                             R        **53**                          390                                                16390                             R
  **15**                           164                                                16164                             R        **54**                          399                                                16399                             R
  **16**                           167                                                16167                             Y        **55**                          463                                                16463                             R
  **17**                           172                                                16172                             Y        **56**                          519                                                16519                             Y
  **18**                           209                                                16209                             Y        **57**                          662                                                 93                               R
  **19**                           217                                                16217                             Y        **58**                          672                                                 103                              R
  **20**                           218                                                16218                             Y        **59**                          715                                                 146                              H
  **21**                           223                                                16223                             Y        **60**                          719                                                 150                              Y
  **22**                           227                                                16227                             R        **61**                          720                                                 151                              Y
  **23**                           234                                                16234                             Y        **62**                          721                                                 152                              Y
  **24**                           235                                                16235                             R        **63**                          722                                                 153                              R
  **25**                           243                                                16243                             H        **64**                          754                                                 185                              R
  **26**                           248                                                16248                             Y        **65**                          758                                                 189                              R
  **27**                           249                                                16249                             Y        **66**                          763                                                 194                              Y
  **28**                           256                                                16256                             Y        **67**                          764                                                 195                              Y
  **29**                           257                                                16257                             H        **68**                          768                                                 199                              Y
  **30**                           260                                                16260                             Y        **69**                          769                                                 200                              R
  **31**                           261                                                16261                             Y        **70**                          773                                                 204                              Y
  **32**                           266                                                16266                             N        **71**                          776                                                 207                              R
  **33**                           272                                                16272                             R        **72**                          779                                                 210                              R
  **34**                           274                                                16274                             R        **73**                          786                                                 217                              Y
  **35**                           278                                                16278                             Y        **74**                          803                                                 234                              R
  **36**                           290                                                16290                             Y        **75**                          804                                                 235                              R
  **37**                           291                                                16291                             Y        **76**                          885                                                 317                              Y
  **38**                           295                                                16295                             Y        **77**                          1019                                                461                              Y
  **39**                           297                                                16297                             Y                                                                                                                        

1.The positions are defined by the aligned sequences from cases and controls. Due to the poor quality at both 5′ and 3′ ends for PCR amplified by primers L15911/H602 as described in materials and methods, the sequences of nt15911--16000 and nt486--602 of the NC_012920 were excluded. nt249/353/354 of the NC_012920 were not included because they were not found in our sequencing data.

2.The position for the D-loop in the Revised Cambridge Reference Sequence ("rCRS"; NC_012920).

D-loop Sequencing {#s2c}
-----------------

The mtDNA control region segment (relative to nucleotide (nt) regions 15911--16569 and 1--602 in the Revised Cambridge Reference Sequence ("rCRS") [@pone.0041125-Andrews1]; NC_012920) was amplified using the forward primer L15911 (5′-ACCAGTCTTGTAAACCGGAG-3′) and the reverse primer H602 (5′-GCTTTGAGGAGGTAAGCTAC-3′). The products were purified with gel extraction kits (Watson BioMedicals Inc.) and sequenced using primer L15911 and primer L29 (5′-CTCACGGGAGCTCTCCATGC-3′) on an ABI 377XL DNA Sequencer (Applied Biosystems, Foster, CA, USA). However, due to the conversion of thymine to cytosine and the presence of homopolymeric cytosine tracts at nt16184--16193 and nt303--315 within the D-loop region of some subjects, the sequencing procedure was prematurely terminated. Therefore, we also performed reverse sequencing using 2 additional sets of primers, H81 (5′-CAGCGTCTCGCAATGCTATC-3′) and H528 (5′-TTCGGGGTATGGGGTTAGCA-3′). The polymerase chain reaction (PCR) conditions used were as follows: an initial denaturation step at 95°C for 5 min, followed by 35 cycles of denaturation at 95°C for 1 min, annealing at 60°C for 1 min, and extension at 68°C for 2 min, with a final extension of 10 min at 72°C. The PCR fragments were analyzed by electrophoresis on a 2% agarose gel and visualized by staining with ethidium bromide.

10.1371/journal.pone.0041125.t003

###### The 9 SNPs with significantly different genotype distributions between patients and controls.
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                               patients   controls   Chi-square         
  -------- -------- --- ----- ---------- ---------- ------------ ------ --------
  total                  897     193                    704             
  SNP 5     16108Y   C   877     185        95.9        692       98.3   0.0419
                     T   20       8         4.1          12       1.7   
  SNP 17    16172Y   C   126      36        18.7         90       12.8   0.0376
                     T   771     157        81.3        614       87.2  
  SNP 21    16223Y   C   394      97        50.3        297       42.2   0.0453
                     T   503      96        49.7        407       57.8  
  SNP 34    16274R   A   13       6         3.1          7        1.0    0.0294
                     G   884     187        96.9        697       99.0  
  SNP 35    16278Y   C   843     188        97.4        655       93.0   0.0238
                     T   54       5         2.6          49       7.0   
  SNP 55    16463R   A   888     188        97.4        700       99.4   0.0125
                     G    9       5         2.6          4        0.6   
  SNP 56    16519Y   C   488     119        61.7        369       52.4   0.0224
                     T   409      74        38.3        335       47.6  
  SNP 64     185R    A   25       14        7.3          11       1.6    0.0000
                     G   872     179        92.7        693       98.4  
  SNP 65     189R    A   874     184        95.3        690       98.0   0.0373
                     G   23       9         4.7          14       2.0   

1The annotation of these SNPs is listed in [Table 2](#pone-0041125-t002){ref-type="table"}.

2SNPs in rCRS position with IUPAC code.

SNP Identification {#s2d}
------------------

DNA sequences were analyzed by using the DNASTAR software and Bio Edit Sequence Alignment Editor freeware (<http://www.mbio.ncsu.edu/bioedit/bioedit.html>). After multiple sequence alignments were performed, both 5′ and 3′ ends of the sequences were trimmed into blunt ends. The SNPs were identified by calculating each nucleotide (A, T, C, or G) for each position in the trimmed and aligned sequences by "count if = " in Excel software. SNP frequencies greater than 1% were selected for further investigation. The SNPs were compared to the D-loop polymorphisms in rCRS as shown in MITOMAP [@pone.0041125-RuizPesini1] (<http://www.mitomap.org/MITOMAP/PolymorphismsControl>).

10.1371/journal.pone.0041125.t004

###### The OR and AOR for the 3 SNPs selected by backward logistic regression.
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  Variable[\*](#nt106){ref-type="table-fn"} ^1^    OR[\*](#nt106){ref-type="table-fn"} ^2^     95% CI      *P* value   AOR[\*](#nt106){ref-type="table-fn"} ^3^     95% CI      *P* value
  ----------------------------------------------- ----------------------------------------- ------------- ----------- ------------------------------------------ ------------- -----------
  SNP 55 G *vs.* A                                                  4.78                     1.26--18.09    0.0212                       1.35                     0.15--12.41    0.7886
  SNP 56 C *vs.* T                                                  1.47                     1.06--2.04     0.0225                       1.41                     0.89--2.24     0.1441
  SNP 64 A *vs.* G                                                  5.15                     2.29--11.60    0.0001                       5.13                     1.61--16.35    0.0057

1.The annotation of these SNPs is listed in [Table 2](#pone-0041125-t002){ref-type="table"}.

2.Odds ratios (ORs) were computed by having only SNP variables in the logistic regression.

3.Adjusted odds ratios (AORs) were computed by having SNP variables in the analysis model with covariates of sex, diabetes mellitus, coronary heart disease, smoker, hypertension, age, body mass index, thiobarbituric acid reactive substance, thiols, triglyceride, and cholesterol.

10.1371/journal.pone.0041125.t005

###### The OR and AOR for the 9 SNPs selected by backward logistic regression for subgroups related to several basic demographic characteristics.
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  (no adjust) [\*](#nt109){ref-type="table-fn"}1    female      male       age\< = 50   age\>50                                                                                                      
  ------------------------------------------------ -------- ------------- ------------ --------- ------------- ----------- ------- -------------- ----------- ------ ------------- ----------- -- -- --
  SNP 5 T *vs.* C                                                                        5.88     1.78--19.44   **0.004**                                                                            
  SNP 17 C *vs.* T                                                                                                          1.81     1.01--3.28    **0.048**                                         
  SNP 21 C *vs.* T                                                                       2.06     1.22--3.47    **0.007**                                                                            
  SNP 34 A *vs.* G                                                                                                                                             5.26   1.15--24.00   **0.032**        
  SNP 35 C *vs.* T                                                                                                                                                                                   
  SNP 55 G *vs.* A                                   6.10    1.10--33.79   **0.039**                                        11.43   1.17--111.50   **0.036**                                         
  SNP 56 C *vs.* T                                                                                                                                                                                   
  SNP 64 A *vs.* G                                  15.24    3.29--70.73   **0.001**                                                                           5.59   1.89--16.57   **0.002**        
  SNP 65 G *vs.* A                                                                       8.14     1.57--42.28   **0.013**                                                                            

  (no adjust) [\*](#nt109){ref-type="table-fn"}1    no DM     no CHD      non smoker   no HT    having HT                                                                                                      
  ------------------------------------------------ ------- ------------- ------------ ------- ------------- ----------- ------ ------------- ----------- ------ ------------- ----------- ------ ------------- -----------
  SNP 5 T *vs.* C                                                                                                        2.81   1.09--7.25    **0.033**                                                        
  SNP 17 C *vs.* T                                                                                                                                                                         3.10   1.48--6.51    **0.003**
  SNP 21 C *vs.* T                                                                                                                                                                                             
  SNP 34 A *vs.* G                                  3.20    1.02--10.00     0.046                                                                                                                              
  SNP 35 C *vs.* T                                                                     3.97    1.22--12.91   **0.022**                                    4.62   1.10--19.41   **0.037**                       
  SNP 55 G *vs.* A                                  4.59    1.14--18.58   **0.033**    5.14    1.36--19.37   **0.016**   5.85   1.38--24.77   **0.016**   6.06   1.33--27.54   **0.020**                       
  SNP 56 C *vs.* T                                                                                                                                                                                             
  SNP 64 A *vs.* G                                  4.13    1.66--10.23   **0.002**    4.52    1.89--10.85   **0.001**   7.02   2.59--19.02   **0.000**   5.20   1.84--14.68   **0.002**                       
  SNP 65 G *vs.* A                                                                                                                                                                         4.46   1.05--18.98   **0.043**

  (Adjust) [\*](#nt109){ref-type="table-fn"}3    female       male       age\< = 50   age\>50                                                                                              
  --------------------------------------------- -------- -------------- ------------ --------- ------------- ------- ------- -------------- ------- ------ ------------- ----------- -- -- --
  SNP 5 T *vs.* C                                                                      4.53     0.80--25.65   0.088                                                                        
  SNP 17 C *vs.* T                                                                                                    1.48     0.55--3.96    0.435                                         
  SNP 21 C *vs.* T                                                                     2.05     0.95--4.40    0.067                                                                        
  SNP 34 A *vs.* G                                                                                                                                   7.97   1.25--50.94   **0.028**        
  SNP 35 C *vs.* T                                                                                                                                                                         
  SNP 55 G *vs.* A                                0.97    0.02--41.98      0.986                                      14.39   0.30--685.42   0.176                                         
  SNP 56 C *vs.* T                                                                                                                                                                         
  SNP 64 A *vs.* G                               35.80    3.23--396.84   **0.004**                                                                   3.67   0.78--17.25     0.100          
  SNP 65 G *vs.* A                                                                     4.84     0.35--67.24   0.240                                                                        

  (Adjust) [\*](#nt109){ref-type="table-fn"}3    no DM     no CHD      non smoker   no HT    having HT                                                                                                      
  --------------------------------------------- ------- ------------- ------------ ------- ------------- ----------- ------ ------------- ----------- ------ ------------- ----------- ------ ------------- -----------
  SNP 5 T *vs.* C                                                                                                     3.02   0.80--11.42     0.102                                                          
  SNP 17 C *vs.* T                                                                                                                                                                      3.71   1.10--12.55   **0.035**
  SNP 21 C *vs.* T                                                                                                                                                                                          
  SNP 34 A *vs.* G                               4.53    1.02--20.21     0.048                                                                                                                              
  SNP 35 C *vs.* T                                                                  3.76    0.84--16.81     0.083                                      5.95   0.73--48.65     0.096                         
  SNP 55 G *vs.* A                               1.55    0.15--15.83     0.713      1.45    0.16--13.54     0.742     2.06   0.16--27.11     0.582     1.97   0.16--24.08     0.595                         
  SNP 56 C *vs.* T                                                                                                                                                                                          
  SNP 64 A *vs.* G                               3.48    0.97--12.55     0.056      4.69    1.44--15.27   **0.010**   5.55   1.38--22.28   **0.016**   4.67   1.02--21.24   **0.046**                       
  SNP 65 G *vs.* A                                                                                                                                                                      4.19   0.41--42.36     0.225

1.Odds ratios (ORs) were computed by having only SNP variables in the logistic regression.

2.Significant SNPs were selected by backward logistic regression for subgroups.

3.Adjusted odds ratios (AORs) were computed by having SNP variables in the analysis model with covariates of sex, diabetes mellitus, coronary heart disease, smoker, hypertension, age, body mass index, thiobarbituric acid reactive substance, thiols, triglyceride, and cholesterol.

4.Adjusted covariates were added in models with significant SNPs.

*P* = *P* value.

Statistical Analysis {#s3}
====================

Chi-square tests were used to compare basic characteristics between patients and controls. A sequence of analyses was adopted for SNP selection. The Chi-square tests were first used to compare distributions of SNPs between patients and controls. Nine SNPs with significant differences and with sufficient cell sizes were chosen for further analysis. These 9 SNPs were included in a logistic regression model with backward selection. Only statistically significant SNPs were selected by logistic regression. The same logistic regression selection process was also conducted for several subgroups. Lastly, the adjusted odds ratios (AOR) from selected SNPs were computed on the basis of logistic regression with additional covariates of basic demographic characteristics ([Table 1](#pone-0041125-t001){ref-type="table"}). The statistical data were expressed as mean ± SD. A *P* value of less than 0.05 was considered as statistically significant.

Results {#s4}
=======

Basic Demographic Characteristics {#s4a}
---------------------------------

The study participants included 193 dialysis patients and 704 healthy controls, and their basic characteristics are shown in [Table 1](#pone-0041125-t001){ref-type="table"}. Most of these characteristics were found to be significantly different, except for age groups and blood TBARS levels. The patients were 3 years younger (49.0±13.9 *vs.* 51.9±12.9) than the controls and had lower values of body mass index (BMI), blood thiols, and cholesterol levels. The mean triglyceride (TG) level was higher in patients than in controls. There was a significantly higher incidence of comorbidities of diabetes, hypertension (HT), and coronary heart disease (CHD) in dialysis patients compared to controls.

D-loop Sequencing, Alignment, and SNP Identification {#s4b}
----------------------------------------------------

There are 2 poly-C regions in the mitochondrial D-loop that stretch between nt16180--16195 [@pone.0041125-Liou1] and nt303--315 [@pone.0041125-Chen1]. Because the length of these mononucleotide repeats varies, they may interfere the sequence alignment processing or lead to error alignment in part. Accordingly, the sequences for these 2 repeat regions were replaced with the corresponding sequences for the reference CRS to improve the performance of sequence alignment. The sequencing data from the 5′ and 3′ ends of nt15911--16000 and nt486--602 were of poor quality and, therefore, were trimmed after confirmation of sequence alignment. Finally, aligned sequences were trimmed to the same length ranging from nt16000--16569 and nt1--485 for further SNP identification ([Table S1](#pone.0041125.s001){ref-type="supplementary-material"} and [Table S2](#pone.0041125.s002){ref-type="supplementary-material"}; all D-loop trimmed sequences for cases and controls and their alignment visualization, respectively). After examining each nt for each position of the trimmed sequence, 77 SNPs with frequencies greater than 1% were identified ([Table S3](#pone.0041125.s003){ref-type="supplementary-material"}). The relationships between positions of the aligned sequences and D-loop in the reference CRS as well as the SNP types in the IUPAC code are listed in [Table 2](#pone-0041125-t002){ref-type="table"}.

Significance Analysis for 77 Individual SNPs {#s4c}
--------------------------------------------

The *P* values for 77 individual SNPs with A, G, C, and T distribution data were analyzed ([Table S4](#pone.0041125.s004){ref-type="supplementary-material"}). Nine SNPs were selected from 77 SNPs by Chi-square tests with significant differences and sufficient cell sizes; their genotype distributions are compared in [Table 3](#pone-0041125-t003){ref-type="table"}. For each SNP, the genotype that appeared at a higher frequency in patients was selected as the indicator. Hence, the indicators for the SNPs 5, 17, 21, 34, 35, 55, 56, 64, and 65 (16108Y, 16172Y, 16223Y, 16274R, 16278Y, 16463R, 16519Y, 185R, and 189R) were T, C, C, A, C, G, C, A, and G, respectively. These 9 indicators were further added into a logistic regression by employing the backward selection method.

Backward Logistic Regression Analysis for 9 SNPs {#s4d}
------------------------------------------------

As shown in [Table 4](#pone-0041125-t004){ref-type="table"}, we identified 3 statistically significant indicators (SNP55 G, SNP56 C, and SNP64 A). Individuals with the SNP55 G increase risk of chronic dialysis by 4.78 times (OR, 95% CI = 1.26∼18.09, *P* = 0.0212). SNP56 C or SNP64 A subjects increase risk of chronic dialysis by 1.47 (95% CI = 1.06∼2.04, *P* = 0.0225) or 5.15 (95% CI = 2.29∼11.60, *P* = 0.0001) times. The AORs of the 3 SNPs were further computed by adding the covariates shown in [Table 1](#pone-0041125-t001){ref-type="table"} into the logistic regression analysis. Following this, only SNP64 A remained significant (OR = 5.13, 95% CI = 1.61∼16.35, *P* = 0.0057). Hence, SNP64 is only an independent SNP for disease as well as for the patients' basic characteristics. On the other hand, while SNP55 and SNP56 found in the backward logistic regression could only be considered as independent SNPs among the 77 SNPs, they were affected by covariates.

Stepwise Regression for Subgroups Related to Several Basic Demographic Characteristics {#s4e}
--------------------------------------------------------------------------------------

Similar procedures were also conducted in several subgroups ([Table 5](#pone-0041125-t005){ref-type="table"}). While the frequencies of SNP55 and SNP64 were found to be significantly higher in women, only those with SNP64 A genotype had a statistically significant higher risk of chronic dialysis (AOR = 35.80, 95% CI = 3.23∼396.84, *P* = 0.004). In subjects older than 50 years, SNP34 A genotype was significantly associated with chronic dialysis (AOR = 7.97, 95% CI = 1.25∼50.94, *P* = 0.028). For subjects without diabetes, without CHD, no smoking habit, or without HT, SNP64 A was the independent SNP in association with chronic dialysis (AOR = 3.48, 4.69, 5.55, and 4.67, *P* = 0.010, 0.016, and 0.046, respectively). For subjects with history of hypertension, SNP17 C was significantly associated with chronic dialysis (AOR = 3.71, 95% CI = 1.10∼12.55, *P* = 0.035).

Discussion {#s5}
==========

To date, most association studies of chronic dialysis focus on the nuclear genome [@pone.0041125-Zheng1]--[@pone.0041125-Wetmore1] rather on mtDNA. In our previous report [@pone.0041125-Chen1], we addressed the association between polymorphisms in the poly-C tract (D310) of the mtDNA D-loop and probability of dialysis treatment. However, we found that the poly-C tract was not significantly different in dialysis patients compared with healthy controls. In addition to the poly-C tract, SNPs are also found in the D-loop. Therefore, we decided to determine whether there was any association between chronic dialysis and SNPs in the D-loop in this study.

Using sequence alignment, we found 9 SNPs present at significantly higher frequency in dialysis patients (SNP5, 17, 21, 34, 35, 55, 56, 64, and 65). Among them, 3 significant indicators (SNP55 G, SNP56 C, and SNP64 A) were independently associated with a high risk of chronic dialysis. Furthermore, only women with the SNP64 A genotype were statistically significant to be associated with chronic dialysis. SNP34 A was significantly associated with chronic dialysis in subjects older than 50 years. For subjects without diabetes, CHD, or hypertension, or in non-smokers, SNP64 A was statistically associated with chronic dialysis. Individuals with history of hypertension were significantly associated with chronic dialysis if they carried SNP17 C.

In this study, we focused solely on the question of whether individual SNPs within the D-loop were associated with chronic dialysis. However, the consideration of interdependence among SNPs was found to improve the association of genetic variations with several diseases [@pone.0041125-Yao1], [@pone.0041125-Lin1] and cancers [@pone.0041125-Briollais1]--[@pone.0041125-Yang2]. Therefore, we cannot exclude the possibility that some rare SNPs may still contribute to the synergistic association with chronic dialysis.

According to the diseases-associated mtSNPs in the D-loop locus in MITOMAP [@pone.0041125-RuizPesini1] (<http://www.mitomap.org/bin/view.pl/MITOMAP/MutationsCodingControl>), only 7 mtSNPs were reported. With reference to the rCRS, these are C114T, C150T, T195C, C309CC, T16189C, A16300G, and C16519T. We only identified C150T (SNP60), T195C (SNP67), and C16519T (SNP56) in our study ([Table 2](#pone-0041125-t002){ref-type="table"}), and of these, only C16519T (SNP56) was significantly associated with chronic dialysis ([Table 3](#pone-0041125-t003){ref-type="table"} and [Table 4](#pone-0041125-t004){ref-type="table"}). Similarly, C16519T was reported to be associated with "cyclic vomiting syndrome with migraine" [@pone.0041125-Boles1], [@pone.0041125-Zaki1]. When stratification of genotypes by demographic characteristics was considered, C16519T did not appear to be a marker associated with chronic dialysis ([Table 5](#pone-0041125-t005){ref-type="table"}). On the contrary, we identified several novel mtSNPs associated with chronic dialysis, suggesting that these mtSNPs are potential genetic markers for this disease.

The acquisition of ROS-induced mutations in CKD may be a consequence of increased oxidative burden in patients with chronic renal failure [@pone.0041125-Chen1], [@pone.0041125-Himmelfarb1], [@pone.0041125-Chen2], [@pone.0041125-Rao1]. For example, elevated oxidative stress in chronic peritoneal dialysis patients may lead to alterations in the mtDNA copy number in peripheral leukocytes [@pone.0041125-Chen2]. In our current study, the mtSNPs listed in [Table 3](#pone-0041125-t003){ref-type="table"} were homoplasmic, as revealed by sequencing chromatograms (data not shown) [@pone.0041125-Reiner1]--[@pone.0041125-Andrew1]. However, we cannot exclude the possibility that a minor fraction of heteroplasmic mutations, below the level of sensitivity of the sequencing method that we used, may be present. We suggest that additional PCR/restriction fragment length polymorphism (RFLP) analysis may assist in the identification of mitochondrial heteroplasmy [@pone.0041125-McFarland1], [@pone.0041125-Wang4]. In light of this, we are unable to identify mtSNPs that are suitable as progression markers for CKD with our current data, since our sequencing method lacked sufficient sensitivity to detect ROS-induced mutations. Therefore, the biological and clinical significance of the homoplasmic mtSNPs are more suitable as potential genetic markers for chronic dialysis, rather than progression markers of CKD.

To the best of our knowledge, this is the first report of SNPs in the mtDNA D-loop showing that they are significantly associated with chronic dialysis. The study also demonstrated the relationship of SNPs with comorbidities in dialysis patients. One may postulate that the presence of these SNPs is a risk factor for the development of end-stage renal disease, and that they may be used as markers to predict the likelihood of dialysis. In the future, further studies are needed to establish the role of these SNPs in the pathophysiology of CKD and to validate their clinical application.
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